Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes.

The underlying molecular pathogenesis in hepatocellular carcinoma remains poorly understood. The transcription factor MEF2D promotes survival in various cell types and it seems to function as an oncogene in leukemia. However, its potential contributions to solid cancers have not been explored. In this study, we investigated MEF2D expression and function in hepatocellular carcinoma, finding that MEF2D elevation in hepatocellular carcinoma clinical specimens was associated with poor prognosis. MEF2D-positive primary hepatocellular carcinoma cells displayed a faster proliferation rate compared with MEF2D-negative cells, and silencing or promoting MEF2D expression in these settings limited or accelerated cell proliferation, respectively. Notably, MEF2D-silencing abolished hepatocellular carcinoma tumorigenicity in mouse xenograft models. Mechanistic investigations revealed that MEF2D-silencing triggered G2-M arrest in a manner associated with direct downregulation of the cell-cycle regulatory genes RPRM, GADD45A, GADD45B, and CDKN1A. Furthermore, we identified MEF2D as an authentic target of miR-122, the reduced expression of which in hepatocellular carcinoma may be responsible for MEF2D upregulation. Together, our results identify MEF2D as a candidate oncogene in hepatocellular carcinoma and a potential target for hepatocellular carcinoma therapy.

[1]  O. Ornatsky,et al.  MEF2 Protein Expression, DNA Binding Specificity and Complex Composition, and Transcriptional Activity in Muscle and Non-muscle Cells* , 1996, The Journal of Biological Chemistry.

[2]  E. Olson,et al.  Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Bucana,et al.  Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. , 1997, Science.

[4]  M E Greenberg,et al.  Neuronal activity-dependent cell survival mediated by transcription factor MEF2. , 1999, Science.

[5]  N. Wong,et al.  A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping , 2000, Hepatology.

[6]  T. Taniguchi,et al.  Reprimo, a New Candidate Mediator of the p53-mediated Cell Cycle Arrest at the G2 Phase* , 2000, The Journal of Biological Chemistry.

[7]  Danielle Hulsman,et al.  Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice , 2002, Nature Genetics.

[8]  Takeshi Suzuki,et al.  New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.

[9]  E. Olson,et al.  MEF2: a calcium-dependent regulator of cell division, differentiation and death. , 2002, Trends in biochemical sciences.

[10]  Yang Shi,et al.  RNA Interference Reveals a Requirement for Myocyte Enhancer Factor 2A in Activity-dependent Neuronal Survival* , 2002, The Journal of Biological Chemistry.

[11]  Jiahuai Han,et al.  Vascular smooth muscle cell proliferation requires both p38 and BMK1 MAP kinases. , 2002, Archives of biochemistry and biophysics.

[12]  Y. Yen,et al.  Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. , 2003, The American journal of pathology.

[13]  Jiing-Dwan Lee,et al.  Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. , 2004, The Journal of clinical investigation.

[14]  S. Friedman,et al.  Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). , 2004, International journal of oncology.

[15]  S. Friedman,et al.  Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. , 2004, Gastroenterology.

[16]  N. Nishida,et al.  Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis , 2005, Genes, chromosomes & cancer.

[17]  I. Wistuba,et al.  Aberrant methylation of Reprimo in human malignancies , 2005, International journal of cancer.

[18]  S. Hunger,et al.  Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia , 2005, Leukemia.

[19]  Steven W. Flavell,et al.  Activity-Dependent Regulation of MEF2 Transcription Factors Suppresses Excitatory Synapse Number , 2006, Science.

[20]  R. Moreira.  Hepatic stellate cells and liver fibrosis. , 2009, Archives of pathology & laboratory medicine.

[21]  S. Hunger,et al.  Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia , 2007, Leukemia.

[22]  John McAnally,et al.  MEF2C transcription factor controls chondrocyte hypertrophy and bone development. , 2007, Developmental cell.

[23]  E. Olson,et al.  MEF2: a central regulator of diverse developmental programs , 2007, Development.

[24]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[25]  J. Subauste,et al.  Retinoic acid responsive genes in the murine hepatocyte cell line AML 12. , 2008, Gene.

[26]  Long Yu,et al.  Gadd45-α and Gadd45-γ utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells , 2009, Molecular Biology Reports.

[27]  Da-Zhi Wang,et al.  The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. , 2008, The Journal of clinical investigation.

[28]  M. Gearing,et al.  Regulation of Neuronal Survival Factor MEF2D by Chaperone-Mediated Autophagy , 2009, Science.

[29]  E. Olson,et al.  Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. , 2009, Blood.

[30]  Leina Ma,et al.  Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. , 2010, Cancer biology & therapy.

[31]  S. Qin,et al.  Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells , 2010, Journal of hematology & oncology.

[32]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[33]  [Expression of MEF2D on nasopharyngeal carcinoma tissues and its influence of prognostic]. , 2011, Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery.

[34]  Leina Ma,et al.  MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. , 2011, Cancer letters.

[35]  Andrew P. Stubbs,et al.  Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. , 2011, Cancer cell.

[36]  Xiaochu Yan,et al.  Nanog regulates self‐renewal of cancer stem cells through the insulin‐like growth factor pathway in human hepatocellular carcinoma , 2012, Hepatology.

[37]  J. C. McDermott,et al.  Suppression of a MEF2-KLF6 Survival Pathway by PKA Signaling Promotes Apoptosis in Embryonic Hippocampal Neurons , 2012, The Journal of Neuroscience.

[38]  G. Feng.  Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. , 2012, Cancer cell.

[39]  Natalie L. Cápiro,et al.  Activation of Transcription Factor MEF2D by Bis(3)-cognitin Protects Dopaminergic Neurons and Ameliorates Parkinsonian Motor Defects* , 2012, The Journal of Biological Chemistry.

[40]  Derek Y. Chiang,et al.  Identification of driver genes in hepatocellular carcinoma by exome sequencing , 2013, Hepatology.

[41]  C. von Kalle,et al.  Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer , 2013, Nature Methods.

[42]  H. M. Reis,et al.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma , 2013, Nature Reviews Cancer.